The Glucagon-like peptide 1 (GLP-1) receptor agonist, exenatide, was the first GPCR targeted drug for type 2 diabetes in 2005, and several more GLP1 receptor agonists have been approved since. Here, GLP1R is linked to type 2 diabetes mellitus.